{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:14:19Z","timestamp":1791267259153,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR301696"],"award-info":[{"award-number":["NIHR301696"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["PGL23\/100048"],"award-info":[{"award-number":["PGL23\/100048"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inherited optic neuropathies (IONs), such as Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (ADOA), typically lead to irreversible severe vision loss due to mitochondrial dysfunction causing retinal ganglion cell degeneration. Although current treatment options are limited, substantial progress has been made recently in our understanding of the molecular genetic pathways that lead to retinal ganglion cell loss. Clinical trials for LHON have demonstrated the efficacy of idebenone, an oral neuroprotective agent, and gene replacement therapy using allotopic gene expression. Early phase clinical trials are underway for ADOA caused by variants in the nuclear gene\n                    <jats:italic>OPA1<\/jats:italic>\n                    using innovative techniques to modulate gene expression in a variant-agnostic manner. In this review, we have critically appraised a range of therapeutic strategies, including gene editing and stem cell-based optic nerve regeneration, with a discussion of the barriers to translation. Future studies focussing on understanding genetic heterogeneity, disease variability and optimising patient selection for clinical trials are essential to\u00a0improve patient management and fast track transformative therapies for IONs.\n                  <\/jats:p>","DOI":"10.1038\/s41433-025-04109-1","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T17:46:47Z","timestamp":1764438407000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advanced therapies for inherited optic neuropathies"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-9527","authenticated-orcid":false,"given":"David Chuen Soong","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-8945","authenticated-orcid":false,"given":"Rahul","family":"Makam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-9320","authenticated-orcid":false,"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"4109_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/1120672119899378","volume":"30","author":"R Jones","year":"2020","unstructured":"Jones R, Al-Hayouti H, Oladiwura D, Karim R, Sawczenko A, Dahlmann-Noor A. Optic atrophy in children: Current causes and diagnostic approach. Eur J Ophthalmol. 2020;30:1499\u2013505.","journal-title":"Eur J Ophthalmol"},{"key":"4109_CR2","doi-asserted-by":"publisher","first-page":"e004015","DOI":"10.1136\/bmjopen-2013-004015","volume":"4","author":"G Liew","year":"2014","unstructured":"Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4:e004015.","journal-title":"BMJ Open"},{"key":"4109_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1212\/WNL.0000000000001995","volume":"85","author":"D Bargiela","year":"2015","unstructured":"Bargiela D, Yu-Wai-Man P, Keogh M, Horvath R, Chinnery PF. Prevalence of neurogenetic disorders in the North of England. Neurology. 2015;85:1195\u2013201.","journal-title":"Neurology"},{"key":"4109_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41431-018-0235-y","volume":"27","author":"N Jurkute","year":"2019","unstructured":"Jurkute N, Majander A, Bowman R, Votruba M, Abbs S, Acheson J, et al. Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches. Eur J Hum Genet. 2019;27:494\u2013502.","journal-title":"Eur J Hum Genet"},{"key":"4109_CR5","doi-asserted-by":"publisher","unstructured":"Eckmann-Hansen C, Bek T, Sander B, Larsen M. Vision-related quality of life and visual ability in patients with autosomal dominant optic atrophy. Acta Ophthalmol [Internet]. 2022 Feb; Available from: https:\/\/doi.org\/10.1111\/aos.15102.","DOI":"10.1111\/aos.15102"},{"key":"4109_CR6","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1167\/iovs.08-3166","volume":"50","author":"MA Kirkman","year":"2009","unstructured":"Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, et al. Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50:3112\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4109_CR7","doi-asserted-by":"publisher","unstructured":"Chen B, Seikus C, Ferguson J, Yu-Wai-Man P, Archer S. \u2018Adrift from the World\u2019: Understanding how inherited optic neuropathies impact on quality of life (S40.002). Neurology [Internet]. 2024 Apr [cited 2024 Sep 15];102. Available from: https:\/\/doi.org\/10.1212\/WNL.0000000000206261.","DOI":"10.1212\/WNL.0000000000206261"},{"key":"4109_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0002-9394(14)76784-4","volume":"111","author":"NJ Newman","year":"1991","unstructured":"Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber\u2019s hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol. 1991;111:750\u201362.","journal-title":"Am J Ophthalmol"},{"key":"4109_CR9","first-page":"249","volume":"17","author":"T Leber","year":"1871","unstructured":"Leber T. Ueber heredit\u00e4re und congenital-angelegte Sehnervenleiden. Arbeitsphysiologie. 1871;17:249\u201391.","journal-title":"Arbeitsphysiologie"},{"key":"4109_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/WNO.0000000000001045","volume":"40","author":"NJ Newman","year":"2020","unstructured":"Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual outcomes in Leber hereditary optic neuropathy patients with the m.11778G>A (MTND4) mitochondrial DNA mutation. J Neuroophthalmol. 2020;40:47\u201357.","journal-title":"J Neuroophthalmol"},{"key":"4109_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41433-021-01535-9","volume":"36","author":"P Yu-Wai-Man","year":"2022","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, La Morgia C, Biousse V, Bandello FM, et al. Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY study. EYE. 2022;36:818\u201326.","journal-title":"EYE"},{"key":"4109_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/bjo.2007.134726","volume":"92","author":"AC Cohn","year":"2008","unstructured":"Cohn AC, Toomes C, Hewitt AW, Kearns LS, Inglehearn CF, Craig JE, et al. The natural history of OPA1-related autosomal dominant optic atrophy. Br J Ophthalmol. 2008;92:1333\u20136.","journal-title":"Br J Ophthalmol"},{"key":"4109_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.preteyeres.2003.10.003","volume":"23","author":"V Carelli","year":"2004","unstructured":"Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23:53\u201389.","journal-title":"Prog Retin Eye Res"},{"key":"4109_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1474-4422(22)00174-0","volume":"22","author":"NJ Newman","year":"2023","unstructured":"Newman NJ, Yu-Wai-Man P, Biousse V, Carelli V. Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. Lancet Neurol. 2023;22:172\u201388.","journal-title":"Lancet Neurol"},{"key":"4109_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100935","volume":"83","author":"G Lenaers","year":"2021","unstructured":"Lenaers G, Neutzner A, Le Dantec Y, J\u00fcschke C, Xiao T, Decembrini S, et al. Dominant optic atrophy: Culprit mitochondria in the optic nerve. Prog Retin Eye Res. 2021;83:100935.","journal-title":"Prog Retin Eye Res"},{"key":"4109_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1187-1","volume":"14","author":"B Le Roux","year":"2019","unstructured":"Le Roux B, Lenaers G, Zanlonghi X, Amati-Bonneau P, Chabrun F, Foulonneau T, et al. OPA1: 516 unique variants and 831 patients registered in an updated centralized Variome database. Orphanet J Rare Dis. 2019;14:214.","journal-title":"Orphanet J Rare Dis"},{"key":"4109_CR17","doi-asserted-by":"publisher","first-page":"e0253987","DOI":"10.1371\/journal.pone.0253987","volume":"16","author":"N Weisschuh","year":"2021","unstructured":"Weisschuh N, Schimpf-Linzenbold S, Mazzola P, Kieninger S, Xiao T, Kellner U, et al. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants. PLoS One. 2021;16:e0253987.","journal-title":"PLoS One"},{"key":"4109_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.mito.2017.07.004","volume":"36","author":"L Caporali","year":"2017","unstructured":"Caporali L, Maresca A, Capristo M, Del Dotto V, Tagliavini F, Valentino ML, et al. Incomplete penetrance in mitochondrial optic neuropathies. Mitochondrion. 2017;36:130\u20137.","journal-title":"Mitochondrion"},{"key":"4109_CR19","doi-asserted-by":"publisher","first-page":"e17963","DOI":"10.1371\/journal.pone.0017963","volume":"6","author":"RH Haefeli","year":"2011","unstructured":"Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One. 2011;6:e17963.","journal-title":"PLoS One"},{"key":"4109_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101812","volume":"38","author":"N Gueven","year":"2021","unstructured":"Gueven N, Ravishankar P, Eri R, Rybalka E. Idebenone: When an antioxidant is not an antioxidant. Redox Biol. 2021;38:101812.","journal-title":"Redox Biol"},{"key":"4109_CR21","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/brain\/awr170","volume":"134","author":"T Klopstock","year":"2011","unstructured":"Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy. Brain. 2011;134:2677\u201386.","journal-title":"Brain"},{"key":"4109_CR22","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1093\/brain\/awr180","volume":"134","author":"V Carelli","year":"2011","unstructured":"Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, et al. Idebenone treatment in Leber\u2019s hereditary optic neuropathy. Brain. 2011;134:e188.","journal-title":"Brain"},{"key":"4109_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","volume":"40","author":"CB Catarino","year":"2020","unstructured":"Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, et al. Real-world clinical experience with idebenone in the treatment of Leber hereditary optic neuropathy. J Neuroophthalmol. 2020;40:558\u201365.","journal-title":"J Neuroophthalmol"},{"key":"4109_CR24","unstructured":"European Medicines Agency (EMA). Raxone [Internet]. European Medicines Agency (EMA). 2015 [cited 2024 Oct 2]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/raxone."},{"key":"4109_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101437","volume":"5","author":"P Yu-Wai-Man","year":"2024","unstructured":"Yu-Wai-Man P, Carelli V, Newman NJ, Silva MJ, Linden A, Van Stavern G, et al. Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial. Cell Rep Med. 2024;5:101437.","journal-title":"Cell Rep Med"},{"key":"4109_CR26","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1093\/brain\/aws280","volume":"136","author":"P Barboni","year":"2013","unstructured":"Barboni P, Valentino ML, La Morgia C, Carbonelli M, Savini G, De Negri A, et al. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain. 2013;136:e231.","journal-title":"Brain"},{"key":"4109_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/acn3.51026","volume":"7","author":"M Romagnoli","year":"2020","unstructured":"Romagnoli M, La Morgia C, Carbonelli M, Di Vito L, Amore G, Zenesini C, et al. Idebenone increases chance of stabilization\/recovery of visual acuity in OPA1-dominant optic atrophy. Ann Clin Transl Neurol. 2020;7:590\u20134.","journal-title":"Ann Clin Transl Neurol"},{"key":"4109_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ophtha.2023.10.033","volume":"131","author":"R Karanjia","year":"2024","unstructured":"Karanjia R, Sadun AA. Elamipretide topical ophthalmic solution for the treatment of subjects with Leber hereditary optic neuropathy: A randomized trial. Ophthalmology. 2024;131:422\u201333.","journal-title":"Ophthalmology"},{"key":"4109_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/archneurol.2011.2972","volume":"69","author":"AA Sadun","year":"2012","unstructured":"Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol. 2012;69:331\u20138.","journal-title":"Arch Neurol"},{"key":"4109_CR30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/hmg\/ddt450","volume":"23","author":"Y Dai","year":"2014","unstructured":"Dai Y, Zheng K, Clark J, Swerdlow RH, Pulst SM, Sutton JP, et al. Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Hum Mol Genet. 2014;23:637\u201347.","journal-title":"Hum Mol Genet"},{"key":"4109_CR31","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1093\/hmg\/ddx373","volume":"26","author":"AK Yu","year":"2017","unstructured":"Yu AK, Datta S, McMackin MZ, Cortopassi GA. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules. Hum Mol Genet. 2017;26:4929\u201336.","journal-title":"Hum Mol Genet"},{"key":"4109_CR32","first-page":"6921","volume":"24","author":"A Pisano","year":"2015","unstructured":"Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, et al. Targeting estrogen receptor \u03b2 as preventive therapeutic strategy for Leber\u2019s hereditary optic neuropathy. Hum Mol Genet. 2015;24:6921\u201331.","journal-title":"Hum Mol Genet"},{"key":"4109_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708734","volume":"11","author":"A Indrieri","year":"2019","unstructured":"Indrieri A, Carrella S, Romano A, Spaziano A, Marrocco E, Fernandez-Vizarra E, et al. miR-181a\/b downregulation exerts a protective action on mitochondrial disease models. EMBO Mol Med. 2019;11:e8734.","journal-title":"EMBO Mol Med"},{"key":"4109_CR34","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/cells12152013","volume":"12","author":"H Shamsnajafabadi","year":"2023","unstructured":"Shamsnajafabadi H, MacLaren RE, Cehajic-Kapetanovic J. Current and future landscape in genetic therapies for Leber hereditary optic neuropathy. Cells. 2023;12:2013.","journal-title":"Cells"},{"key":"4109_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ana.10354","volume":"52","author":"J Guy","year":"2002","unstructured":"Guy J, Qi X, Pallotti F, Schon EA, Manfredi G, Carelli V, et al. Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol. 2002;52:534\u201342.","journal-title":"Ann Neurol"},{"key":"4109_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamaophthalmol.2013.7630","volume":"132","author":"RD Koilkonda","year":"2014","unstructured":"Koilkonda RD, Yu H, Chou T-H, Feuer WJ, Ruggeri M, Porciatti V, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014;132:409\u201320.","journal-title":"JAMA Ophthalmol"},{"key":"4109_CR37","first-page":"55","volume":"28","author":"H Pei","year":"2013","unstructured":"Pei H, Wan X, Hu W, Dong X, Li B. Construction and detection of a novel type of recombinant human rAAV2\/2-ND4. Eye Sci. 2013;28:55\u20139.","journal-title":"Eye Sci"},{"key":"4109_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.3","volume":"2","author":"H Cwerman-Thibault","year":"2015","unstructured":"Cwerman-Thibault H, Augustin S, Lechauve C, Ayache J, Ellouze S, Sahel J-A, et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Mol Ther Methods Clin Dev. 2015;2:15003.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4109_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archophthalmol.2010.135","volume":"128","author":"RD Koilkonda","year":"2010","unstructured":"Koilkonda RD, Chou T-H, Porciatti V, Hauswirth WW, Guy J. Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol. 2010;128:876\u201383.","journal-title":"Arch Ophthalmol"},{"key":"4109_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","volume":"125","author":"C Vignal","year":"2018","unstructured":"Vignal C, Uretsky S, Fitoussi S, Galy A, Blouin L, Girmens J-F, et al. Safety of rAAV2\/2-ND4 gene therapy for Leber hereditary optic neuropathy. Ophthalmology. 2018;125:945\u20137.","journal-title":"Ophthalmology"},{"key":"4109_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40259-021-00468-9","volume":"35","author":"C Vignal-Clermont","year":"2021","unstructured":"Vignal-Clermont C, Girmens J-F, Audo I, Said SM, Errera M-H, Plaine L, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: The REVEAL study. BioDrugs. 2021;35:201\u201314.","journal-title":"BioDrugs"},{"key":"4109_CR42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","volume":"128","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset. Ophthalmology. 2021;128:649\u201360.","journal-title":"Ophthalmology"},{"key":"4109_CR43","doi-asserted-by":"publisher","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med [Internet]. 2020 Dec;12. Available from: https:\/\/doi.org\/10.1126\/scitranslmed.aaz7423.","DOI":"10.1126\/scitranslmed.aaz7423"},{"key":"4109_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WNO.0000000000001367","volume":"41","author":"V Biousse","year":"2021","unstructured":"Biousse V, Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Vignal-Clermont C, et al. Long-term follow-up after unilateral intravitreal gene therapy for Leber hereditary optic neuropathy: The RESTORE study. J Neuroophthalmol. 2021;41:309\u201315.","journal-title":"J Neuroophthalmol"},{"key":"4109_CR45","doi-asserted-by":"publisher","first-page":"662838","DOI":"10.3389\/fneur.2021.662838","volume":"12","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Biousse V, Moster ML, Vignal-Clermont C, et al. Intravitreal gene therapy vs. Natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A ND4 mutation: Systematic review and indirect comparison. Front Neurol. 2021;12:662838.","journal-title":"Front Neurol"},{"key":"4109_CR46","first-page":"99","volume":"143","author":"P Yu-Wai-Man","year":"2025","unstructured":"Yu-Wai-Man P, Newman NJ, Biousse V, Carelli V, Moster ML, Vignal-Clermont C, et al. Five-year Outcomes of Lenadogene Nolparvovec gene therapy in Leber hereditary optic neuropathy. JAMA Ophthalmol Am Med Assoc. 2025;143:99\u2013108.","journal-title":"JAMA Ophthalmol Am Med Assoc"},{"key":"4109_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/brain\/awac421","volume":"146","author":"NJ Newman","year":"2023","unstructured":"Newman NJ, Yu-Wai-Man P, Subramanian PS, Moster ML, Wang A-G, Donahue SP, et al. Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy. Brain. 2023;146:328\u201341.","journal-title":"Brain"},{"key":"4109_CR48","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1007\/s40123-022-00611-x","volume":"12","author":"V Carelli","year":"2023","unstructured":"Carelli V, Newman NJ, Yu-Wai-Man P, Biousse V, Moster ML, Subramanian PS, et al. Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in patients with Leber hereditary optic neuropathy carrying the m.11778G>A MT-ND4 mutation. Ophthalmol Ther. 2023;12:01\u201329.","journal-title":"Ophthalmol Ther"},{"key":"4109_CR49","doi-asserted-by":"crossref","unstructured":"Newman NJ, Biousse V, Yu-Wai-Man P, Carelli V, Vignal-Clermont C, Montestruc F, et al. Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy. Surv Ophthalmol. 2024 Oct [cited 2024 Oct 29];0(0). Available from: http:\/\/www.surveyophthalmol.com\/article\/S0039625724001309\/abstract.","DOI":"10.1016\/j.survophthal.2024.10.002"},{"key":"4109_CR50","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","volume":"123","author":"WJ Feuer","year":"2016","unstructured":"Feuer WJ, Schiffman JC, Davis JL, Porciatti V, Gonzalez P, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: Initial results. Ophthalmology. 2016;123:558\u201370.","journal-title":"Ophthalmology"},{"key":"4109_CR51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, et al. Gene therapy for Leber hereditary optic neuropathy: Low- and medium-dose visual results. Ophthalmology. 2017;124:1621\u201334.","journal-title":"Ophthalmology"},{"key":"4109_CR52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajo.2022.02.023","volume":"241","author":"BL Lam","year":"2022","unstructured":"Lam BL, Feuer WJ, Davis JL, Porciatti V, Yu H, Levy RB, et al. Leber hereditary optic neuropathy gene therapy: Adverse events and visual acuity results of all patient groups. Am J Ophthalmol. 2022;241:262\u201371.","journal-title":"Am J Ophthalmol"},{"key":"4109_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep21587","volume":"6","author":"X Wan","year":"2016","unstructured":"Wan X, Pei H, Zhao M-J, Yang S, Hu W-K, He H, et al. Efficacy and safety of rAAV2-ND4 treatment for leber\u2019s hereditary optic neuropathy. Sci Rep. 2016;6:21587.","journal-title":"Sci Rep"},{"key":"4109_CR54","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Ma S-Q, Wan X, He H, Pei H, Zhao M-J, et al. Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy. EBioMedicine. 2016;10:258\u201368.","journal-title":"EBioMedicine"},{"key":"4109_CR55","doi-asserted-by":"publisher","first-page":"e730","DOI":"10.1111\/aos.14379","volume":"98","author":"H Liu","year":"2020","unstructured":"Liu H, Yuan J, Zhang Y, Tian Z, Li X, Wang D, et al. Factors associated with rapid improvement in visual acuity in patients with Leber\u2019s hereditary optic neuropathy after gene therapy. Acta Ophthalmol. 2020;98:e730\u20133.","journal-title":"Acta Ophthalmol"},{"key":"4109_CR56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ceo.13515","volume":"47","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li X, Yuan J, Tian Z, Liu H, Wang D, et al. Prognostic factors for visual acuity in patients with Leber\u2019s hereditary optic neuropathy after rAAV2-ND4 gene therapy. Clin Exp Ophthalmol. 2019;47:774\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"4109_CR57","doi-asserted-by":"publisher","first-page":"15927","DOI":"10.1073\/pnas.0407043101","volume":"101","author":"S Cipolat","year":"2004","unstructured":"Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA. 2004;101:15927\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4109_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.phrs.2018.02.018","volume":"131","author":"V Del Dotto","year":"2018","unstructured":"Del Dotto V, Fogazza M, Lenaers G, Rugolo M, Carelli V, Zanna C. OPA1: How much do we know to approach therapy? Pharm Res. 2018;131:199\u2013210.","journal-title":"Pharm Res"},{"key":"4109_CR59","doi-asserted-by":"publisher","unstructured":"Harvey JP, Yu-Wai-Man P, Cheetham ME. Characterisation of a novel OPA1 splice variant resulting in cryptic splice site activation and mitochondrial dysfunction. Eur J Hum Genet [Internet]. 2022 May; Available from: https:\/\/doi.org\/10.1038\/s41431-022-01102-0","DOI":"10.1038\/s41431-022-01102-0"},{"key":"4109_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/WNO.0000000000001830","volume":"43","author":"DCS Wong","year":"2023","unstructured":"Wong DCS, Harvey JP, Jurkute N, Thomasy SM, Moosajee M, Yu-Wai-Man P, et al. OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets. J Neuroophthalmol. 2023;43:464\u201374.","journal-title":"J Neuroophthalmol"},{"key":"4109_CR61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbabio.2018.01.005","volume":"1859","author":"V Del Dotto","year":"2018","unstructured":"Del Dotto V, Fogazza M, Carelli V, Rugolo M, Zanna C. Eight human OPA1 isoforms, long and short: What are they for? Biochim Biophys Acta Bioenerg. 2018;1859:263\u20139.","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"4109_CR62","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awq007","volume":"133","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771\u201386.","journal-title":"Brain"},{"key":"4109_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20838-8","volume":"8","author":"E Sarzi","year":"2018","unstructured":"Sarzi E, Seveno M, Piro-M\u00e9gy C, Elzi\u00e8re L, Quil\u00e8s M, P\u00e9quignot M, et al. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model. Sci Rep. 2018;8:2468.","journal-title":"Sci Rep"},{"key":"4109_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.571479","volume":"14","author":"DM Maloney","year":"2020","unstructured":"Maloney DM, Chadderton N, Millington-Ward S, Palfi A, Shortall C, O\u2019Byrne JJ, et al. Optimized OPA1 isoforms 1 and 7 provide therapeutic benefit in models of mitochondrial dysfunction. Front Neurosci. 2020;14:571479.","journal-title":"Front Neurosci"},{"key":"4109_CR65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.omtn.2021.08.015","volume":"26","author":"PE Sladen","year":"2021","unstructured":"Sladen PE, Perdig\u00e3o PRL, Salsbury G, Novoselova T, van der Spuy J, Chapple JP, et al. CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs. Mol Ther Nucleic Acids. 2021;26:432\u201343.","journal-title":"Mol Ther Nucleic Acids"},{"key":"4109_CR66","doi-asserted-by":"publisher","unstructured":"Harvey JP, Sladen PE, Yu-Wai-Man P, Cheetham ME. Induced Pluripotent Stem Cells for Inherited Optic Neuropathies-Disease Modeling and Therapeutic Development. J Neuroophthalmol [Internet]. 2021; Available from: https:\/\/doi.org\/10.1097\/WNO.0000000000001375.","DOI":"10.1097\/WNO.0000000000001375"},{"key":"4109_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.627050","volume":"12","author":"S-RA Hussain","year":"2021","unstructured":"Hussain S-RA, Yalvac ME, Khoo B, Eckardt S, McLaughlin KJ. Adapting CRISPR\/Cas9 system for targeting mitochondrial genome. Front Genet. 2021;12:627050.","journal-title":"Front Genet"},{"key":"4109_CR68","doi-asserted-by":"publisher","first-page":"305716","DOI":"10.1155\/2015\/305716","volume":"2015","author":"A Jo","year":"2015","unstructured":"Jo A, Ham S, Lee GH, Lee Y-I, Kim S, Lee Y-S, et al. Efficient mitochondrial genome editing by CRISPR\/Cas9. Biomed Res Int. 2015;2015:305716.","journal-title":"Biomed Res Int"},{"key":"4109_CR69","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41434-023-00434-w","volume":"31","author":"S Eghbalsaied","year":"2024","unstructured":"Eghbalsaied S, Lawler C, Petersen B, Hajiyev RA, Bischoff SR, Frankenberg S. CRISPR\/Cas9-mediated base editors and their prospects for mitochondrial genome engineering. Gene Ther. 2024;31:209\u201323.","journal-title":"Gene Ther"},{"key":"4109_CR70","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41586-020-2477-4","volume":"583","author":"BY Mok","year":"2020","unstructured":"Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583:631\u20137.","journal-title":"Nature"},{"key":"4109_CR71","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41587-022-01486-w","volume":"41","author":"S Lee","year":"2023","unstructured":"Lee S, Lee H, Baek G, Kim J-S. Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors. Nat Biotechnol. 2023;41:378\u201386.","journal-title":"Nat Biotechnol"},{"key":"4109_CR72","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41587-023-01791-y","volume":"42","author":"Z Yi","year":"2024","unstructured":"Yi Z, Zhang X, Tang W, Yu Y, Wei X, Zhang X, et al. Strand-selective base editing of human mitochondrial DNA using mitoBEs. Nat Biotechnol. 2024;42:498\u2013509.","journal-title":"Nat Biotechnol"},{"key":"4109_CR73","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s12276-023-00973-7","volume":"55","author":"HTL Phan","year":"2023","unstructured":"Phan HTL, Lee H, Kim K. Trends and prospects in mitochondrial genome editing. Exp Mol Med. 2023;55:871\u20138.","journal-title":"Exp Mol Med"},{"key":"4109_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.80","volume":"2","author":"GS Gorman","year":"2016","unstructured":"Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial diseases. Nat Rev Dis Prim. 2016;2:16080.","journal-title":"Nat Rev Dis Prim"},{"key":"4109_CR75","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/emmm.201303672","volume":"6","author":"PA Gammage","year":"2014","unstructured":"Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med. 2014;6:458\u201366.","journal-title":"EMBO Mol Med"},{"key":"4109_CR76","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41591-018-0165-9","volume":"24","author":"PA Gammage","year":"2018","unstructured":"Gammage PA, Viscomi C, Simard M-L, Costa ASH, Gaude E, Powell CA, et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med. 2018;24:1691\u20135.","journal-title":"Nat Med"},{"key":"4109_CR77","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/mt.2015.126","volume":"23","author":"M Hashimoto","year":"2015","unstructured":"Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, et al. MitoTALEN: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol Ther. 2015;23:1592\u20139.","journal-title":"Mol Ther"},{"key":"4109_CR78","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41591-018-0166-8","volume":"24","author":"SR Bacman","year":"2018","unstructured":"Bacman SR, Kauppila JHK, Pereira CV, Nissanka N, Miranda M, Pinto M, et al. MitoTALEN reduces mutant mtDNA load and restores tRNAAla levels in a mouse model of heteroplasmic mtDNA mutation. Nat Med. 2018;24:1696\u2013700.","journal-title":"Nat Med"},{"key":"4109_CR79","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tjo.2011.09.001","volume":"1","author":"P Yu-Wai-Man","year":"2011","unstructured":"Yu-Wai-Man P, Chinnery PF. Leber hereditary optic neuropathy - therapeutic challenges and early promise. Taiwan J Ophthalmol. 2011;1:12\u20135.","journal-title":"Taiwan J Ophthalmol"},{"key":"4109_CR80","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.molmed.2020.02.006","volume":"26","author":"CB Jackson","year":"2020","unstructured":"Jackson CB, Turnbull DM, Minczuk M, Gammage PA. Therapeutic manipulation of mtDNA heteroplasmy: A shifting perspective. Trends Mol Med. 2020;26:698\u2013709.","journal-title":"Trends Mol Med"},{"key":"4109_CR81","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nature18303","volume":"534","author":"LA Hyslop","year":"2016","unstructured":"Hyslop LA, Blakeley P, Craven L, Richardson J, Fogarty NME, Fragouli E, et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016;534:383\u20136.","journal-title":"Nature"},{"key":"4109_CR82","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/d41586-023-01585-x","volume":"617","author":"E Callaway","year":"2023","unstructured":"Callaway E. First UK children born using three-person IVF: what scientists want to know. Nature. 2023;617:443\u20134.","journal-title":"Nature"},{"key":"4109_CR83","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(18)31868-3","volume":"392","author":"GS Gorman","year":"2018","unstructured":"Gorman GS, McFarland R, Stewart J, Feeney C, Turnbull DM. Mitochondrial donation: from test tube to clinic. Lancet. 2018;392:1191\u20132.","journal-title":"Lancet"},{"key":"4109_CR84","doi-asserted-by":"publisher","unstructured":"Hyslop LA, Blakely EL, Aushev M, Marley J, Takeda Y, Pyle A, et al. Mitochondrial donation and preimplantation genetic testing for mtDNA disease. N Engl J Med [Internet]. 2025 Jul [cited 2025 Jul 17];(NEJMoa2415539). Available from: https:\/\/doi.org\/10.1056\/nejmoa2415539.","DOI":"10.1056\/nejmoa2415539"},{"key":"4109_CR85","doi-asserted-by":"publisher","unstructured":"McFarland R, Hyslop LA, Feeney C, Pillai RN, Blakely EL, Moody E, et al. Mitochondrial donation in a reproductive care pathway for mtDNA disease. N Engl J Med [Internet]. 2025 Jul [cited 2025 Jul 17];(NEJMoa2503658). Available from: https:\/\/doi.org\/10.1056\/nejmoa2503658.","DOI":"10.1056\/nejmoa2503658"},{"key":"4109_CR86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/20502877.2018.1440725","volume":"24","author":"L Craven","year":"2018","unstructured":"Craven L, Murphy J, Turnbull DM, Taylor RW, Gorman GS, McFarland R. Scientific and ethical issues in mitochondrial donation. N Bioeth. 2018;24:57\u201373.","journal-title":"N Bioeth"},{"key":"4109_CR87","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/biomedicines12051110","volume":"12","author":"Z Ma","year":"2024","unstructured":"Ma Z, Sharma R, Rogers AN. Physiological consequences of nonsense-mediated decay and its role in adaptive responses. Biomedicines. 2024;12:1110.","journal-title":"Biomedicines"},{"key":"4109_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/nat.2024.0022","volume":"34","author":"A Venkatesh","year":"2024","unstructured":"Venkatesh A, McKenty T, Ali S, Sonntag D, Ravipaty S, Cui Y, et al. Antisense oligonucleotide STK-002 increases OPA1 in retina and improves mitochondrial function in autosomal dominant optic atrophy cells. Nucleic Acid Ther. 2024;34:221\u201333.","journal-title":"Nucleic Acid Ther"},{"key":"4109_CR89","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A. N = 1 Collaborative. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med. 2024;4:6.","journal-title":"Commun Med"},{"key":"4109_CR90","doi-asserted-by":"publisher","unstructured":"Gross S. A study to investigate the safety, tolerability, and exposure of single doses of the study medicine STK-002, in patients with autosomal dominant optic atrophy (ADOA) [Internet]. http:\/\/isrctn.com\/. Springer Science and Business Media LLC; 2023 [cited 2024 Oct 18]. Available from: https:\/\/doi.org\/10.1186\/ISRCTN41725621.","DOI":"10.1186\/ISRCTN41725621"},{"key":"4109_CR91","first-page":"88","volume":"65","author":"M Votruba","year":"2024","unstructured":"Votruba M, Yu-Wai-Man P, Saluti K, Wang Y, Ticho B, Gross S. OSPREY: An open-label study to investigate safety, tolerability, and exposure of the antisense oligonucleotide (ASO) STK-002 in patients with autosomal dominant optic atrophy (ADOA). Invest Ophthalmol Vis Sci. 2024;65:88.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4109_CR92","first-page":"5305","volume":"65","author":"J Grainok","year":"2024","unstructured":"Grainok J, Utama S, Chai T, Ong F, Champain D, Lui G, et al. PYC-001: A promising RNA therapeutic for autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2024;65:5305.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4109_CR93","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/gbe\/evw025","volume":"8","author":"Q Lei","year":"2016","unstructured":"Lei Q, Li C, Zuo Z, Huang C, Cheng H, Zhou R. Evolutionary insights into RNA trans-splicing in vertebrates. Genome Biol Evol. 2016;8:562\u201377.","journal-title":"Genome Biol Evol"},{"key":"4109_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/bmb\/ldaa028","volume":"136","author":"EM Hong","year":"2020","unstructured":"Hong EM, Ingemarsdotter CK, Lever AML. Therapeutic applications of trans-splicing. Br Med Bull. 2020;136:4\u201320.","journal-title":"Br Med Bull"},{"key":"4109_CR95","doi-asserted-by":"crossref","unstructured":"le Dantec Y, Baris O, Lenaers G. OPA1 trans-splicing: A gene therapy approach to treat OPA1-related optic neuropathies. Acta Ophthalmol [Internet]. 2022 Dec [cited 2024 Oct 18];100. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1755-3768.2022.15427.","DOI":"10.1111\/j.1755-3768.2022.15427"},{"key":"4109_CR96","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-023-00655-y","volume":"18","author":"JR Soucy","year":"2023","unstructured":"Soucy JR, Aguzzi EA, Cho J, Gilhooley MJ, Keuthan C, Luo Z, et al. Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium. Mol Neurodegener. 2023;18:64.","journal-title":"Mol Neurodegener"},{"key":"4109_CR97","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40135-020-00259-5","volume":"8","author":"LK Wareham","year":"2020","unstructured":"Wareham LK, Risner ML, Calkins DJ. Protect, repair, and regenerate: Towards restoring vision in glaucoma. Curr Ophthalmol Rep. 2020;8:301\u201310.","journal-title":"Curr Ophthalmol Rep"},{"key":"4109_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10472","volume":"7","author":"P Venugopalan","year":"2016","unstructured":"Venugopalan P, Wang Y, Nguyen T, Huang A, Muller KJ, Goldberg JL. Transplanted neurons integrate into adult retinas and respond to light. Nat Commun. 2016;7:10472.","journal-title":"Nat Commun"},{"key":"4109_CR99","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s12035-018-1154-1","volume":"56","author":"LA Mesentier-Louro","year":"2019","unstructured":"Mesentier-Louro LA, Rosso P, Carito V, Mendez-Otero R, Santiago MF, Rama P, et al. Nerve growth factor role on retinal ganglion cell survival and axon regrowth: Effects of ocular administration in experimental model of optic nerve injury. Mol Neurobiol. 2019;56:1056\u201369.","journal-title":"Mol Neurobiol"},{"key":"4109_CR100","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature10594","volume":"480","author":"F Sun","year":"2011","unstructured":"Sun F, Park KK, Belin S, Wang D, Lu T, Chen G, et al. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature. 2011;480:372\u20135.","journal-title":"Nature"},{"key":"4109_CR101","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1460-9568.2007.05321.x","volume":"25","author":"ACE Symonds","year":"2007","unstructured":"Symonds ACE, King CE, Bartlett CA, Sauv\u00e9 Y, Lund RD, Beazley LD, et al. EphA5 and ephrin-A2 expression during optic nerve regeneration : a \u2018two-edged sword. Eur J Neurosci. 2007;25:744\u201352.","journal-title":"Eur J Neurosci"},{"key":"4109_CR102","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.stemcr.2017.05.035","volume":"9","author":"J-F Feng","year":"2017","unstructured":"Feng J-F, Liu J, Zhang L, Jiang J-Y, Russell M, Lyeth BG, et al. Electrical guidance of human stem cells in the rat brain. Stem Cell Rep. 2017;9:177\u201389.","journal-title":"Stem Cell Rep"},{"key":"4109_CR103","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/ijms18092013","volume":"18","author":"T-C Yang","year":"2017","unstructured":"Yang T-C, Chuang J-H, Buddhakosai W, Wu W-J, Lee C-J, Chen W-S, et al. Elongation of axon extension for human iPSC-derived retinal ganglion cells by a nano-imprinted scaffold. Int J Mol Sci. 2017;18:2013.","journal-title":"Int J Mol Sci"},{"key":"4109_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2015.11.036","volume":"164","author":"F Bei","year":"2016","unstructured":"Bei F, Lee HHC, Liu X, Gunner G, Jin H, Ma L, et al. Restoration of visual function by enhancing conduction in regenerated axons. Cell. 2016;164:219\u201332.","journal-title":"Cell"},{"key":"4109_CR105","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nn.4340","volume":"19","author":"J-HA Lim","year":"2016","unstructured":"Lim J-HA, Stafford BK, Nguyen PL, Lien BV, Wang C, Zukor K, et al. Neural activity promotes long-distance, target-specific regeneration of adult retinal axons. Nat Neurosci. 2016;19:1073\u201384.","journal-title":"Nat Neurosci"},{"key":"4109_CR106","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.4103\/1673-5374.193251","volume":"11","author":"JN Weiss","year":"2016","unstructured":"Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber\u2019s hereditary optic neuropathy. Neural Regen Res. 2016;11:1685\u201394.","journal-title":"Neural Regen Res"},{"key":"4109_CR107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21037\/sci.2019.11.01","volume":"6","author":"JN Weiss","year":"2019","unstructured":"Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy. Stem Cell Investig. 2019;6:41.","journal-title":"Stem Cell Investig"},{"key":"4109_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100390","volume":"3","author":"TV Johnson","year":"2023","unstructured":"Johnson TV, Baranov P, Di Polo A, Fortune B, Gokoffski KK, Goldberg JL, et al. The Retinal Ganglion Cell Repopulation, Stem Cell Transplantation, and Optic Nerve Regeneration Consortium. Ophthalmol Sci. 2023;3:100390.","journal-title":"Ophthalmol Sci"},{"key":"4109_CR109","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","volume":"37","author":"V Carelli","year":"2017","unstructured":"Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagr\u00e8ze WA, et al. International consensus statement on the clinical and therapeutic management of Leber hereditary optic neuropathy. J Neuroophthalmol. 2017;37:371\u201381.","journal-title":"J Neuroophthalmol"},{"key":"4109_CR110","first-page":"60","volume":"12","author":"C Morgia","year":"2024","unstructured":"Morgia C, Klopstock T, Yu-Wai-Man P. Idebenone treatment for Leber hereditary optic neuropathy: Time to clinically relevant recovery in the LEROS study. Eur Med J. 2024;12:60\u20133.","journal-title":"Eur Med J"},{"key":"4109_CR111","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ophtha.2009.07.026","volume":"117","author":"P Barboni","year":"2010","unstructured":"Barboni P, Carbonelli M, Savini G, Ramos CdoVF, Carta A, Berezovsky A, et al. Natural history of Leber\u2019s hereditary optic neuropathy: longitudinal analysis of the retinal nerve fiber layer by optical coherence tomography. Ophthalmology. 2010;117:623\u20137.","journal-title":"Ophthalmology"},{"key":"4109_CR112","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/bjophthalmol-2015-307326","volume":"100","author":"N Balducci","year":"2016","unstructured":"Balducci N, Savini G, Cascavilla ML, La Morgia C, Triolo G, Giglio R, et al. Macular nerve fibre and ganglion cell layer changes in acute Leber\u2019s hereditary optic neuropathy. Br J Ophthalmol. 2016;100:1232\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4109_CR113","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mito.2017.03.002","volume":"36","author":"N Balducci","year":"2017","unstructured":"Balducci N, Ciardella A, Gattegna R, Zhou Q, Cascavilla ML, La Morgia C, et al. Optical coherence tomography angiography of the peripapillary retina and optic nerve head in dominant optic atrophy. Mitochondrion. 2017;36:60\u20135.","journal-title":"Mitochondrion"},{"key":"4109_CR114","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/02713683.2019.1567792","volume":"44","author":"S Asanad","year":"2019","unstructured":"Asanad S, Tian JJ, Frousiakis S, Jiang JP, Kogachi K, Felix CM, et al. Optical Coherence Tomography of the Retinal Ganglion Cell Complex in Leber\u2019s Hereditary Optic Neuropathy and Dominant Optic Atrophy. Curr Eye Res. 2019;44:638\u201344.","journal-title":"Curr Eye Res"},{"key":"4109_CR115","unstructured":"https:\/\/www.rnib.org.uk\/living-with-sight-loss\/equality-and-employment\/information-for-those-in-work\/assistive-technology\/ Assistive Technology [Internet]. RNIB. [cited 2025 Jul 1]."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04109-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:03:26Z","timestamp":1769173406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04109-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04109-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PYWM is a consultant for GenSight Biologics, Chiesi, Neurophth Therapeutics, Stoke Therapeutics and PYC Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}